

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF NEW YORK**

NOVO NORDISK A/S AND NOVO  
NORDISK INC.,

Plaintiffs,

v.

FLAWLESS IMAGE MEDICAL  
AESTHETICS, LLC,

Defendant.

Case No. 5:23-cv-00739 (GTS/ML)

**COMPLAINT FOR TRADEMARK INFRINGEMENT,  
FALSE ADVERTISING, AND UNFAIR COMPETITION**

Plaintiffs Novo Nordisk A/S (“NNAS”) and Novo Nordisk Inc. (“NNI”) (collectively, “Plaintiffs” or “Novo Nordisk”), by and through their attorneys, King & Spalding LLP, file their complaint against Flawless Image Medical Aesthetics, LLC (“Defendant”) for injunctive and other relief. Plaintiffs allege as follows, upon actual knowledge with respect to themselves and their own acts, and upon information and belief as to all other matters.

**INTRODUCTION**

1. Novo Nordisk is a healthcare company with a 100-year history of innovation in developing medicines to treat serious chronic diseases like diabetes and obesity.
2. The development of semaglutide is an example of Novo Nordisk’s commitment to innovation for people living with chronic diseases. Semaglutide is the foundational molecule which serves as the primary ingredient for Novo Nordisk’s three prescription-only medicines approved by the Food and Drug Administration (“FDA”): Wegovy® (semaglutide) injection 2.4 mg, for chronic weight management, and Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Rybelsus® (semaglutide) tablets 7 mg or 14 mg, both for adults with type 2 diabetes.

3. Novo Nordisk is the only company in the U.S. with FDA-approved products containing semaglutide. Novo Nordisk is also the only company authorized to identify its products containing semaglutide using the trademarks Wegovy®, Ozempic®, and Rybelsus®. The FDA has not approved any generic versions of semaglutide.

4. This is an action brought pursuant to the Lanham Act, 15 U.S.C. §§ 1051 et seq., related state laws and the common law, arising out of Defendant's infringement of Plaintiffs' rights in their Ozempic® and Wegovy® marks and Defendant's acts of false advertising and unfair competition.

**Novo Nordisk's FDA-Approved Semaglutide Products,  
Ozempic® and Wegovy®, and Registered Trademarks**

5. Plaintiffs use the trademarks "Ozempic" and "Wegovy" to identify and promote the FDA-approved drugs, Ozempic® and Wegovy®. Ozempic® and Wegovy® are sold and marketed in the United States by NNAS's, indirect, wholly-owned subsidiary, NNI.

6. Wegovy® is indicated for chronic weight management in adults and children aged  $\geq 12$  years with obesity (BMI  $\geq 30$  for adults, BMI  $\geq 95^{\text{th}}$  percentile for age and sex for children), or some adults with excess weight (BMI  $\geq 27$ ) (overweight) with weight-related medical problems, along with a reduced calorie meal plan and increased physical activity.

7. Ozempic® is indicated for adults with type 2 diabetes to improve blood sugar (glucose), along with diet and exercise. Ozempic® also lowers the risk of major cardiovascular events such as stroke, heart attack or death in adults with type 2 diabetes and known heart disease.

8. Each of Wegovy® and Ozempic® has a unique safety and efficacy profile which is detailed in its respective product label.

9. Wegovy® and Ozempic® are prescription-only medicines that should only be prescribed in direct consultation with, and under the supervision of, a licensed healthcare professional.

10. Wegovy® and Ozempic® have been extensively studied in clinical trials and are FDA-approved.

11. Novo Nordisk does not sell its FDA-approved semaglutide products, Ozempic® and Wegovy®, to Defendant, for resale or redistribution.

12. Novo Nordisk first adopted and used the Ozempic® mark at least as early as 2018, and has used it continuously since that time. Novo Nordisk has extensively promoted, advertised and marketed its prescription-only medicines bearing the Ozempic® mark in many different channels, directed both to physicians and other health care professionals and to consumers.

13. As a result of its use of the Ozempic® mark, NNAS owns valuable common law rights in and to the Ozempic® mark.

14. Novo Nordisk first adopted and used the Wegovy® mark at least as early as 2021, and has used it continuously since that time. Novo Nordisk has extensively promoted, advertised and marketed its prescription-only medicine bearing the Wegovy® mark in many different channels, directed both to physicians and other health care professionals and to consumers.

15. As a result of its use of the Wegovy® mark, NNAS owns valuable common law rights in and to the Wegovy® mark.

**Defendant's Trademark Infringement and False Advertising  
in Connection With its Sale to Patients of Unapproved Compounded Drugs**

16. Defendant markets and sells to patients compounded drug products that purport to contain semaglutide and that are not approved by the FDA (“Unapproved Compounded Drugs”).

17. On information and belief, the Unapproved Compounded Drugs sold by Defendant are made by compounding pharmacies, which deliver them to Defendant for administration or dispensing to patients.

18. The FDA defines compounding as a “practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.” See <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding>.

19. According to the FDA, “[c]ompounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”

20. The FDA has further stated that: “Compounded drugs . . . do not have the same safety, quality, and effectiveness assurances as approved drugs. Unnecessary use of compounded drugs unnecessarily exposes patients to potentially serious health risks. Because compounded drugs are not FDA-approved, FDA does not verify their safety, effectiveness or quality before they are marketed.”<sup>1</sup>

21. On May 31, 2023, FDA issued guidance on “medications containing semaglutide marketed for Type 2 diabetes or weight loss,” which provides that: (1) “compounded drugs are not FDA-approved, and the agency does not verify the safety or effectiveness of compounded drugs”; and (2) “FDA has received adverse event reports after patients used compounded semaglutide. Patients should not use a compounded drug if an approved drug is available to treat

---

<sup>1</sup> Compounding and the FDA: Questions and Answers, <https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>.

a patient. Patients and health care professionals should understand that the agency does not review compounded versions of these drugs for safety, effectiveness, or quality.”

22. Defendant uses Novo Nordisk’s Wegovy® and Ozempic® trademarks to market and sell Unapproved Compounded Drugs purporting to contain “semaglutide” that are neither Wegovy® nor Ozempic®. Defendant unlawfully uses Novo Nordisk’s trademarks to attract customers and generate revenues and profits, including by passing off as Wegovy® or Ozempic® its own Unapproved Compounded Drugs purporting to contain “semaglutide.”

23. Defendant first started using Novo Nordisk’s Wegovy® and Ozempic® marks to advertise its Unapproved Compounded Drugs well after NNAS’s first use and registration of its Wegovy® and Ozempic® marks.

24. Defendant also falsely advertises its Unapproved Compounded Drugs on its website by making statements that describe Wegovy® and Ozempic®, but are false or misleading as to Defendant’s Unapproved Compounded Drugs.

25. Defendant has made misleading statements in advertising and promotion that claim or imply that its Unapproved Compounded Drugs have been approved by FDA and/or have been subjected to clinical studies and trials.

26. Defendant continues to use the Wegovy® and Ozempic® marks, including in advertising and promotion on its website and on printed materials given to its customers who, upon information and belief, are seeking to buy but are in fact not buying genuine Wegovy® and Ozempic® products.

27. Defendant’s prominent and misleading use of the Wegovy® and Ozempic® marks is likely to cause consumers to falsely believe that they are actually purchasing genuine Wegovy® and Ozempic® products, that Defendant is a source for Novo Nordisk’s FDA-approved

products, and/or that Defendant's services are provided, licensed, sponsored, authorized, or approved by Novo Nordisk.

28. Defendant's use of the Wegovy® and Ozempic® marks is without the permission, consent or authorization of Novo Nordisk. Defendant has no right to use, and Defendant knows that it has no right to use, the Wegovy® and Ozempic® marks in connection with Defendant's Unapproved Compounded Drugs or otherwise.

29. Novo Nordisk has no control over the nature, quality or efficacy of the products sold by Defendant, including the Unapproved Compounded Drugs.

### **THE PARTIES**

30. Plaintiff NNAS is a corporation organized and existing under the laws of the Kingdom of Denmark and has its principal place of business in Bagsværd, Denmark.

31. Plaintiff NNI is a Delaware corporation and has its principal place of business in Plainsboro, New Jersey.

32. NNI promotes, offers, and/or sells Novo Nordisk's Wegovy® and Ozempic® products throughout the United States, including in this District. NNAS has granted to NNI exclusive rights to market, advertise, promote, offer for sale and sell Wegovy® and Ozempic® products in the United States.

33. Defendant is a Delaware limited liability company with a registered address at 651 N. Broad Street, Suite 201, Middleton, Delaware 19709. Defendant operates its business at 5805 Bridge Street, East Syracuse, New York 13057, in this judicial district. Defendant sells and promotes Unapproved Compounded Drugs masquerading as Wegovy® or Ozempic® and/or uses the Wegovy® and Ozempic® marks in its advertising and promotion of Unapproved Compounded Drugs that are not Wegovy® or Ozempic®.

### **JURISDICTION AND VENUE**

34. The Court has subject matter jurisdiction over the Lanham Act causes of action pleaded herein pursuant to 35 U.S.C. § 1121 and 28 U.S.C. § 1338(a). The Court has supplemental jurisdiction over the state and common law causes of action pleaded herein pursuant to 28 U.S.C. § 1338(b).

35. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Defendant operates in this District, manufactures and/or sells its Unapproved Compounded Drugs in this District, and otherwise conducts business in this District. Defendant is subject to personal jurisdiction in this District.

**NOVO NORDISK'S OZEMPIC® AND WEGOVY® TRADEMARKS**

36. Plaintiff NNAS is the owner of U.S. trademark registration number 4,774,881, issued on July 21, 2015, for the mark OZEMPIC for pharmaceutical preparations, in International Class 5. A true and correct copy of Plaintiff NNAS's registration for the OZEMPIC® mark is attached hereto as **Exhibit A**.

37. Plaintiff NNAS is the owner of (a) U.S. trademark registration number 6,585,492, issued on December 14, 2021, for the mark WEGOVY for pharmaceutical preparations, in International Class 5; and (b) U.S. trademark registration number 6,763,029, issued on June 21, 2022, for the mark WEGOVY in a stylized form for pharmaceutical preparations, in International Class 5. True and correct copies of Plaintiff's registrations numbers 6,585,492 and 6,763,029 for the WEGOVY® mark are attached hereto as **Exhibit B** and **Exhibit C**, respectively.

38. The Wegovy® and Ozempic® trademarks are inherently distinctive.

39. Novo Nordisk promotes and advertises its Wegovy® and Ozempic® products through various channels, including on the websites ozempic.com, wegovy.com, and/or novonordisk-us.com, and to physicians and licensed healthcare professionals, among others.

40. As a result of Novo Nordisk's long use, promotion, and advertising of the Wegovy® and Ozempic® trademarks and products, the Wegovy® and Ozempic® marks are exclusively associated with Plaintiffs, serve to identify genuine Novo Nordisk products, and are valuable assets of Novo Nordisk.

41. As a result of Novo Nordisk's long use, promotion, and advertising of the Wegovy® and Ozempic® trademarks and products, the Wegovy® and Ozempic® trademarks are well-known, strong and famous marks, and became famous prior to any of the acts of Defendant complained of herein.

#### **DEFENDANT'S INFRINGING USE OF THE OZEMPIC® AND WEGOVY® MARKS**

42. Long after Novo Nordisk's first use of the Ozempic® mark at least as early as 2017 and first use of the Wegovy® mark at least as early as 2021, long after NNAS's priority dates of 2014 for the Ozempic® trademark and 2020 for the Wegovy® trademark, and long after NNAS secured federal registrations for the Wegovy® and Ozempic® marks in 2021 and 2015, respectively, Defendant started using the Wegovy® and Ozempic® marks in commercial advertising and promotion to promote its Unapproved Compounded Drugs in a false and misleading way. Examples of Defendant's trademark infringement and false advertising are attached hereto as **Exhibit D**.<sup>2</sup>

43. Defendant started using the Wegovy® and Ozempic® marks, including on its website, after Plaintiffs first used and secured federal registrations for those marks.

44. Defendant promotes its Unapproved Compounded Drugs on its website and on its social media with messages such as "Get Wegovy!", "Ozempic Wegovy® reduces appetite,"

---

<sup>2</sup> Identifying information has been redacted from the social media images captured in Exhibit D.

“How do Wegovy/Ozempic Work,” “How Wegovy Produces Weight Loss,” and “Get Evaluated for Wegovy/Ozempic.”

45. The images below are true and correct representations of information on Defendant’s website, <https://www.flawlessimagedspa.com/>, as of the date of this Complaint.



46. Defendant also promotes its Unapproved Compounded Drugs by making literally false statements, which imply that Defendant's Unapproved Compounded Drugs purporting to contain semaglutide are FDA-approved, which is not true. The image below is a true and correct representation of information on Defendant's website as of the date of this Complaint.

## Weight Loss Program (Semaglutide/Wegovy/Ozempic or Phentermine)

Semaglutide is a new FDA-approved weight loss treatment that has recently hit the headlines. Just like many others are discovering, this injectable may be the solution for your weight management and metabolic health.

Flawless Image is a leading provider of Semaglutide weight loss injections in Syracuse. Many patients who do not have access in Canada to these medications have come and are welcome at our office to receive treatment. Call 315-694-6243 to schedule a free consultation with our team which is overseen by board certified Dr. Phillip Din. Read on to learn about Semaglutide, also known as Wegovy and Ozempic, and how it can help you reach your weight loss goal.

47. Defendant's labels, advertising and promotional materials are false and misleading, suggesting and/or stating an association with Plaintiffs' FDA-approved Wegovy® and Ozempic® products, when no such association exists.

48. There is no need for Defendant to use the Wegovy® and Ozempic® trademarks to advertise or promote its Unapproved Compounded Drugs purporting to contain "semaglutide," other than to trade upon the reputation of Plaintiffs and to create confusion in the marketplace and/or mislead the public regarding the origin, identity or source of Defendant's Unapproved Compounded Drugs.

49. Defendant's unauthorized use of the Wegovy® and Ozempic® trademarks is likely to cause confusion, to cause mistake, or to deceive, and infringes Plaintiffs' established exclusive rights in those trademarks.

50. Upon information and belief, unless enjoined by this Court, Defendant will continue to use the Wegovy® and Ozempic® marks and/or otherwise falsely advertise its products as associated with or being Wegovy® and Ozempic®, all in violation of Plaintiffs' rights.

**FIRST CAUSE OF ACTION**

**(Trademark Infringement in Violation of 15 U.S.C. § 1114(1))**

51. Plaintiff NNAS realleges and incorporates by reference each of the allegations contained in paragraphs 1-50 of this Complaint as though fully set forth here.

52. Plaintiff NNAS's Wegovy® and Ozempic® marks are inherently distinctive, strong, valid, and protectable trademarks owned by Plaintiff NNAS.

53. Plaintiff NNAS's registration for its Ozempic® mark is incontestable and therefore constitutes conclusive evidence of the validity of the mark, of Plaintiff NNAS's registration and ownership of the mark, and of Plaintiff NNAS's exclusive right to use the mark in commerce on or in connection with the goods identified in the registration.

54. Plaintiff NNAS's trademark registrations for its Wegovy® marks constitute *prima facie* evidence of the validity of the marks, of Plaintiff NNAS's registration and ownership of the marks, and of Plaintiff NNAS's exclusive right to use the mark in commerce on or in connection with the goods identified in the registrations.

55. By virtue of its prior use and registrations, Plaintiff NNAS has priority over Defendant with respect to the use of the Wegovy® and Ozempic® marks for pharmaceutical preparations sold in the United States.

56. Defendant uses the Wegovy® and Ozempic® marks in connection with the sale, advertising, and promotion of Unapproved Compounded Drugs purporting to contain semaglutide.

57. Defendant's use in commerce of the Wegovy® and Ozempic® marks is likely to cause confusion, to cause mistake, or to deceive with respect to Plaintiff NNAS's identical marks.

58. The above-described acts of Defendant constitute infringement of registered trademarks in violation of Section 32(1) of the Lanham Act, 15 U.S.C. § 1114(1), entitling Plaintiff NNAS to relief.

59. Defendant has unfairly profited from its trademark infringement.

60. By reason of Defendant's acts of trademark infringement, Plaintiff NNAS has suffered damage to the goodwill associated with its marks.

61. Defendant's acts of trademark infringement have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiff NNAS, its federally registered trademarks and the valuable goodwill associated with those trademarks.

62. Defendant's acts of trademark infringement have irreparably harmed, and if not enjoined, will continue to irreparably harm the interests of the public in being free from confusion, mistake, and deception.

63. By reason of Defendant's acts, Plaintiff NNAS's remedies at law are not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiff NNAS is entitled to entry of preliminary and permanent injunctive relief pursuant to 15 U.S.C. § 1116.

64. By reason of Defendant's willful acts of trademark infringement, Plaintiff NNAS is entitled to treble damages under 15 U.S.C. § 1117.

65. This is an exceptional case, making Plaintiff NNAS eligible for an award of attorneys' fees under 15 U.S.C. § 1117.

**SECOND CAUSE OF ACTION**

**(Trademark Infringement, Use of False Designation of Origin and  
Unfair Competition in Violation of 15 U.S.C. § 1125(a)(1)(A))**

66. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-50 of this Complaint as though fully set forth here.

67. Defendant uses the Wegovy® and Ozempic® marks in commerce in connection with Defendant's goods and services and in commercial advertising and promotion of its goods and services.

68. Defendant uses the Wegovy® and Ozempic® marks in commerce in a manner that is likely to cause confusion, or to cause mistake, or to deceive the relevant public into believing that Defendant's goods or services are authorized, sponsored, approved by, or otherwise affiliated with Plaintiffs, with Plaintiffs' genuine Wegovy® and Ozempic® products, and/or with the Wegovy® and Ozempic® marks.

69. The above-described acts of Defendant constitute infringement of the Wegovy® and Ozempic® marks and use of false designations of origin in violation of Section 43(a)(1)(A) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(A), entitling Plaintiffs to relief.

70. Defendant has unfairly profited from the actions alleged.

71. By reason of the above-described acts of Defendant, Plaintiffs have suffered damage to the goodwill associated with the Wegovy® and Ozempic® trademarks.

72. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs, the Wegovy® and Ozempic® trademarks, and the valuable goodwill associated with the trademarks.

73. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

74. By reason of Defendant's acts, Plaintiffs' remedies at law are not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief pursuant to 15 U.S.C. § 1116.

75. Because the above-described acts of Defendant are willful, Plaintiffs are entitled to treble damages under 15 U.S.C. § 1117.

76. This is an exceptional case, making Plaintiffs eligible for an award of attorneys' fees under 15 U.S.C. § 1117.

### **THIRD CAUSE OF ACTION**

#### **(Defendant's False and Misleading Advertising and Promotion in Violation of 15 U.S.C. § 1125(a)(1)(B))**

77. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-50 of this Complaint as though fully set forth here.

78. Defendant's practices, as described in this Complaint, constitute unfair competition and false advertising in violation of Section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).

79. Defendant has violated the Lanham Act by using false or misleading descriptions of fact and false or misleading representations of fact in its commercial advertising or promotion that misrepresent the nature, characteristics, and/or qualities of Defendant's business practices and products, as set forth above.

80. Defendant has also engaged in other false or misleading advertising and promotion intended to assure consumers that Defendant's practices are lawful. Upon

information and belief, Flawless Image Medical Aesthetics provides consumers who purchase Defendant's Unapproved Compounded Drugs (or whom Defendant is trying to persuade to purchase its drugs) information that makes several false or misleading statements, including:

81. Defendant makes the statement on its website that semaglutide is "FDA-approved", which falsely implies that Defendant's Unapproved Compounded Drugs are FDA-approved, which they are not.

82. The above-described acts of Defendant, if not enjoined by this Court, are likely to deceive members of the general public.

83. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs.

84. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

85. By reason of Defendant's acts as alleged above, Plaintiffs have suffered and will continue to suffer injuries, including injury to Plaintiffs' business reputation. However, Plaintiffs' remedies at law are not adequate to compensate for all the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief requiring Defendant to cease its false and misleading advertising and promotion and unfair competitive practices.

#### **FOURTH CAUSE OF ACTION**

##### **(Common Law Unfair Competition)**

86. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-50 of this Complaint as though fully set forth here.

87. The above-described acts of Defendant constitute common law unfair competition.

88. The above-described acts of Defendant unfairly and wrongfully exploit Plaintiffs' trademarks, goodwill and reputation.

89. By reason of the above-described acts of Defendant, Plaintiffs have suffered damage to the goodwill associated with the Wegovy® and Ozempic® trademarks.

90. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs and the Wegovy® and Ozempic® trademarks.

91. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

92. By reason of Defendant's acts, Plaintiffs' remedies at law are not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief, in addition to monetary relief in the form of disgorgement of Defendant's profits, and corrective advertising costs.

#### **FIFTH CAUSE OF ACTION**

##### **(Violation of New York General Business Law § 349)**

93. Plaintiffs reallege and incorporate by reference each of the allegations contained in paragraphs 1-50 of this Complaint as though fully set forth here.

94. The above-described acts of Defendant constitute deceptive acts and practices in violation of the laws of the State of New York, including New York General Business Law § 349.

95. New York General Business Law § 349 prohibits deceptive acts or practices in the conduct of any business, trade or commerce.

96. The above-described acts of Defendant are made in the conduct of Defendant's business, trade or commerce.

97. The above-described acts of Defendant wrongfully exploit Plaintiffs' trademarks in a manner likely to deceive the public.

98. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm Plaintiffs and the trademarks.

99. The above-described acts of Defendant have irreparably harmed and, if not enjoined, will continue to irreparably harm the interest of the public in being free from confusion, mistake, and deception.

100. Members of the public are also likely to suffer injury from the above-described acts of Defendant by purchasing a drug that they believe to be Plaintiffs' FDA-approved products, Wegovy® or Ozempic®, not an Unapproved Compounded Drug that does not have the same safety, quality, and effectiveness assurances as approved drugs.

101. By reason of the above-described acts of Defendant, Plaintiffs have suffered damage to the goodwill associated with its trademarks.

102. Defendant has unfairly profited from the actions alleged.

103. By reason of Defendant's acts, Plaintiffs' remedy at law is not adequate to compensate for the injuries inflicted by Defendant. Accordingly, Plaintiffs are entitled to entry of preliminary and permanent injunctive relief, in addition to monetary relief in the form of disgorgement of Defendant's profits, and corrective advertising costs.

**REQUEST FOR RELIEF**

WHEREFORE, Plaintiffs request judgment against Defendant as follows:

1. That the Court enter a judgment against Defendant that Defendant has:
  - a. Infringed the rights of Plaintiff NNAS in its federally registered Wegovy® and Ozempic® marks, in violation of 15 U.S.C. § 1114(1);
  - b. Infringed the rights of Plaintiffs in the Wegovy® and Ozempic® marks and engaged in unfair competition, in violation of 15 U.S.C. § 1125(a);
  - c. Engaged in false and misleading advertising and promotion, in violation of 15 U.S.C. § 1125(a);
  - d. Engaged in unfair competition under the common law of New York and New York General Business Law § 349.
2. That each of the above acts was willful.
3. That the Court preliminarily and permanently enjoin and restrain Defendant and its agents, servants, employees, successors and assigns, and all other persons acting in concert with or in conspiracy with or affiliated with Defendant, from:
  - a. Using the trademarks Wegovy® and/or Ozempic®, or any marks, names or designations confusingly similar to either of them, in connection with the advertising, promoting, marketing, selling or offering for sale of any goods or services (including, but not limited to, Unapproved Compounded Drugs) or otherwise engaging in any activity that is likely to cause confusion, cause mistake or deceive or otherwise infringes any rights of Plaintiffs in and to the Wegovy® and Ozempic® marks or any similar marks;
  - b. Falsely stating or suggesting that any Unapproved Compounded Drugs are genuine Wegovy® and Ozempic® products, that Defendant is associated or

- connected in any way with Plaintiffs or Plaintiffs' products, or that Defendant's Unapproved Compounded Drugs are approved by the FDA;
- c. Falsely stating or suggesting that Defendant's Unapproved Compounded Drugs have been proven to achieve certain therapeutic results or effects;
  - d. Engaging in any unfair competition with Plaintiffs; and/or
  - e. Engaging in any deceptive acts or practices.
4. Requiring Defendant, its agents, servants, employees, successors and assigns, and all other persons acting in concert with or in conspiracy with or affiliated with Defendant, to engage in corrective advertising by informing consumers that Defendant is not and never has been authorized, affiliated, sponsored, approved, or related to Plaintiffs or genuine Wegovy® and Ozempic® products and that Defendant's Unapproved Compounded Drugs are not and have never been genuine Wegovy® and Ozempic® products or approved by the FDA.
  5. That Plaintiffs be awarded monetary relief in the form of disgorgement of Defendant's profits for Defendant's trademark infringement, false advertising and unfair competition and that this monetary relief be trebled due to Defendant's willfulness, in accordance with the provisions of 15 U.S.C. § 1117 and any applicable state laws.
  6. That Plaintiffs be awarded all Defendants' profits resulting from Defendant's infringement of Plaintiffs' rights and by means of Defendant's unfair competition.
  7. That Defendant be ordered to account for and disgorge to Plaintiffs all amounts by which Defendant has been unjustly enriched by reason of Defendant's unlawful actions.
  8. That Plaintiffs be awarded punitive damages by reason of Defendant's willful unlawful actions.
  9. For pre-judgment and post-judgment interest on all damages.

10. That the Court award Plaintiffs their reasonable attorneys' fees pursuant to 15 U.S.C. § 1117, New York General Business Law § 349, and any other applicable provision of law.

11. That the Court award Plaintiffs the costs of suit incurred herein.

12. For such other or further relief as the Court may deem just and proper.

DATED: June 20, 2023

Respectfully submitted,

By: /s/ Kathleen E. McCarthy  
Kathleen E. McCarthy  
New York Bar No. 2125722  
**King & Spalding LLP**  
1185 Avenue of the Americas, 34<sup>th</sup> Floor  
New York, NY 10036-2601  
(212) 556-2100  
[kmccarthy@kslaw.com](mailto:kmccarthy@kslaw.com)

Aaron Craig  
(*Pro hac vice application forthcoming*)  
633 West Fifth Street, Suite 1600  
Los Angeles, CA 90071  
(213) 443-4355  
[acraig@kslaw.com](mailto:acraig@kslaw.com)

Bruce Baber  
(*Pro hac vice application forthcoming*)  
1180 Peachtree Street, NE, Suite 1600  
Atlanta, GA 30309-3521  
(404) 572-4600  
[bbaber@kslaw.com](mailto:bbaber@kslaw.com)

*Attorneys for Plaintiffs*  
**NOVO NORDISK A/S and**  
**NOVO NORDISK INC.**